June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Topical Infliximab as an inhibitor of corneal hemangiogenesis and lymphangiogenesis
Author Affiliations & Notes
  • Giulio Ferrari
    Ophthalmology -Cornea Unit-Eye Repair, San Raffaele Scientific Institute, Milan, Italy
  • Fabio Bignami
    Ophthalmology -Cornea Unit-Eye Repair, San Raffaele Scientific Institute, Milan, Italy
  • Chiara Giacomini
    Ophthalmology -Cornea Unit-Eye Repair, San Raffaele Scientific Institute, Milan, Italy
  • Paolo Rama
    Ophthalmology -Cornea Unit-Eye Repair, San Raffaele Scientific Institute, Milan, Italy
  • Footnotes
    Commercial Relationships Giulio Ferrari, None; Fabio Bignami, None; Chiara Giacomini, None; Paolo Rama, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2099. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Giulio Ferrari, Fabio Bignami, Chiara Giacomini, Paolo Rama; Topical Infliximab as an inhibitor of corneal hemangiogenesis and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2099.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To test whether topical application of the anti-TNF alpha antibody Infliximab can reduce lymphangiogenesis and/or hemangiogenesis in an alkali burn mouse model of corneal neovascularization.

Methods: Eighteen C57BL/6 mice were induced alkali burn model of the right cornea. Animals were then divided in two groups: group 1 received topical Infliximab 10mg/ml six times a day (10ul), group 2 received regular saline. After two weeks, animals were sacrificed, corneas stained for CD31 and LYVE1 to identify hemangiogenesis and lymphangiogenesis. Finally, the corneas were whole mounted and imaged. Neovascularization was calculated as neovascular area, i.e. the area of the cornea covered by vessels normalized for the total area of the cornea.

Results: Following topical application of Infliximab hemangiogenesis decreased from 0.81±0.12 to 0.6±0.24 (26% reduction, P<0.05). Lymphangiogenesis was also reduced from 0.11± 0.04 to 0.05± 0.02 (55% reduction, P<0.001), after topical treatment with Infliximab.

Conclusions: Topical application of Infliximab 10mg/ml for two weeks is effective in reducing corneal hemangiogenesis and lymphangiogenesis in a mouse model of corneal alkali burn. Interestingly, Infliximab appeared more effective inhibting lymphangiogenesis than hemangiogenesis. Given the high prevalence of corneal neovascularization in a wide range of corneal diseases, we suggest these findings may have implications in the treatment of corneal neovascularization in human subjects.

Keywords: 765 wound healing • 480 cornea: basic science • 557 inflammation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×